Incyte Corporation is in the biotechnology industry and trades as part of the healthcare sector. The company CEO is Herve Hoppenot. Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.
Previous Intraday Trading Performance:
The INCY stock showed a previous change of -2.05% with an open at 81.38 and a close of 79.40. It reached an intraday high of 81.78 and a low of 79.21.
SeekingAlpha: Stifel neutral on Incyte in premarket analyst action
The stock has a market cap of $17.0b with 214.3m shares outstanding, of which the float is 211.6m shares. Trading volume reached 1,721,589 shares compared to its average volume of 1,179,131 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Incyte Corporation shares returned -5.96% and in the past 30 trading days it returned -7.04%. Over three months, it changed 0.81%. In one year it has changed 12.83% and within that year its 52-week high was 88.83 and its 52-week low was 57.00. INCY stock is 39.30% above its 52 Week Low.
Our calculations show a 200 day moving average of 72.17 and a 50 day moving average of 84.14. Currently INCY stock is trading 10.02% above its 200 day moving average.
Business Wire: Incyte to Report First Quarter Financial Results
The last annual fiscal EPS for the company was reported at 0.51 that ended on 31st of December 2018, which according to the previous close, that is a PE of 155.69. Based on 1 analyst estimate, the estimated EPS for the next quarter is 0.23. The TTM EPS is 0.50, which comes to a TTM PE of 158.80.
Base on our calculations, the intrinsic value per share is 92.07, which means it is possibly undervalued and has a margin of safety of 13.76%
Indicators to Watch:
Based on the latest filings, there is 1.20% of insider ownership and 124.40% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.
The current calculated beta is 1.35
SeekingAlpha: Syros Pharmaceuticals Platform Undervalued After Dip
Based on last reported financials, the company’s return on equity is 6.16%, return on assets is 4.43%, profit margin is 10.05%, price-to-sales is 11.58 and price-to-book is 8.83.
All scores are out of six:
0 :Valuation Score
1 :Past Performance Score
6 :Financial Strength Score
4 :Future Growth Score
0 :Dividend Score
2 :Overall Score